Condition category
Circulatory System
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart condition. One in every 500 people have the condition and there are one million sufferers in Europe. It is a disorder of the heart muscle (myocardium) itself results in
heart muscle thickening (hypertrophy) and scarring (fibrosis). This condition can cause disturbances in heart rhythms which can cause sudden death, indeed HCM is the leading cause of sudden death in young (<35 years old) people. HCM hearts process energy inefficiently, and progressive heart failure can also develop. There are currently no treatments that alter the natural history of the disease. It is not clear how the faulty gene causes the muscle to become thickened, however current research suggests that it is a problem with our body cells not being able to use energy properly. Trientine is a medication used to treat Wilson disease, a rare disorder which leads to excess copper accumulation and tissue damage since 1969. It also acts on energy usage to improve it. Trientine has been found to reduce heart muscle hypertrophy in patients with diabetes. The aim of this study is to investigate whether Trientine will reduce the thickening of the heart in HCM patients, improve its energy efficiency and therefore represent the first disease modifying therapy in HCM.

Who can participate?
Adults (aged at least 18) with HCM

What does the study involve?
Partipicants are randomly allocated into one of two groups. Those in group 1 receive their usual care. Those in group 2 are given trientine for 6 months. All patients undergo cardiac magnetic resonance (CMR) imaging at the start of the study and then after 6 months of therapy. CMR assesses how the heart uses its energy, myocardial hypertrophy and fibrosis.

What are the possible benefits and risks of participating?
Not provided at time of registration

Where is the study run from?
Wythenshawe Hospital (UK)

When is the study starting and how long is it expected to run for?
October 2014 to October 2015

Who is funding the study?
Medical Research Council (UK)

Who is the main contact?
Dr Anna Reid

Trial website

Contact information



Primary contact

Dr Anna Reid


Contact details

Wythenshawe Hospital
Southmoor Road
M23 9LT
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Copper chelation in hypertrophic cardiomyopathy: open-label pilot study of trientine in patients with hypertrophic cardiomyopathy


Study hypothesis

Trientine will lead to left ventricular mass regression in hypertrophic cardiomyopathy, and improvement in myocardial energetics is associated with, or causative of, this LV regression.

Ethics approval

NRES Committee North West- Liverpool East, 26/06/2014, ref: 14/NW/1015

Study design

Non-randomised; Interventional

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Topic: Cardiovascular disease; Subtopic: Cardiovascular (all Subtopics); Disease: Cardiovascular


Using trientine to assess if it improves fitness and heart function to improve treatment options for HCM. Participants will receive trientine for 6 months.

Intervention type



Not Applicable

Drug names


Primary outcome measure

Myocardial energetics, measured using cardiac MRI prior to starting treatment and at the end of treatment

Secondary outcome measures


Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Male or female > 18 years of age
2. Females will be non-pregnant and non-lactating with no intention of pregnancy during study treatment (see point 6)
3. Confirmed diagnosis of HCM in line with 2011 ACCF / AHA consensus document
4. Positive genotype
5. LV ejection fraction = 50%
6. Women of childbearing potential (not >1 year post-menopausal) must agree to use one of the following acceptable birth control methods:
6.1. True complete abstinence when this is in line with the preferred and usual lifestyle of the subject
6.2. Surgical sterilization of either the female subject in study (e.g., bilateral tubal ligation) or of her male partner (vasectomy with documented azoospermia) if he is the sole partner of that subject
6.3. Established progesterone-only hormonal contraception (implantable, patch, oral or intramuscular [IM]) administered for at least one month prior to study medication administration
6.4. Double barrier method: condom and occlusive cap (diaphragm) with spermicidal foam/gel/film/ cream/suppository

Participant type


Age group




Target number of participants

Planned Sample Size: 20; UK Sample Size: 20

Total final enrolment


Participant exclusion criteria

1. History of any other cardiovascular disorder, including aortic stenosis, aortic coarctation, hypertension, renal artery stenosis, atrial fibrillation
2. NYHA Class III/IV heart failure
3. Diabetes mellitus
4. Contraindication to magnetic resonance imaging (MRI) scanning (including claustrophobia)
5. Known hypersensitivity to Trientine or excipients
6. Known hypersensitivity to Gadolinium-based contrast agent
7. eGFR < 50ml/min/1.73m2
8. BMI > 40kg/m2
9. History of significant malabsorption
10. Copper deficiency at baseline
11. Iron deficiency at baseline
12. Haemoglobin < 10g/dL
13. Unresolved haematological disorder
14. Severe hepatic impairment
15. Untreated thyroid disease
16. Autoimmune disorders/connective tissue disease
17. Drug or alcohol abuse
18. Pregnancy/breast-feeding. Women of childbearing potential (not >2 years post- menopausal and/or not surgically sterilised) must have a negative blood serum pregnancy test, performed at visit 1 prior to administration of study medication
19. Any clinically significant or unstable medical or psychiatric condition that would interfere with the patient’s ability to participate in the study
20. Any other condition, which in the opinion of the research team, may put participants at risk during the study, or which may affect the outcome of the study
21. New medication within the preceding month of the study (excluding short term prescriptions)
22. Participation in another study involving an investigational product in the previous 12 weeks

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Wythenshawe Hospital
Southmoor Road Wythenshawe
M23 9LT
United Kingdom

Sponsor information


University Hospital of South Manchester NHS Foundation Trust

Sponsor details

Southmoor Road
M23 9LT
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Medical Research Council

Alternative name(s)


Funding Body Type

government organisation

Funding Body Subtype

National government


United Kingdom

Results and Publications

Publication and dissemination plan

To be confirmed at a later date

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

2017 results in (added 04/11/2020)

Publication citations

Additional files

Editorial Notes

04/11/2020: The following changes have been made: 1. Publication reference added. 2. The total final enrolment number has been added from the reference. 14/11/2017: No publications found, verifying study status with principal investigator.